Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase
- PMID: 17635179
- DOI: 10.1111/j.1472-8206.2007.00520.x
Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase
Abstract
Cytochrome P450 proteins are involved in metabolism of drugs and xenobiotics. In the endoplasmic reticulum a single nicotinamide adenine dinucleotide phosphate (NADPH) P450 oxidoreductase (POR) supplies electrons to all microsomal P450s for catalytic activity. POR is a flavoprotein that contains both flavin mononucleotide and flavin adenine dinucleotide as cofactors and uses NADPH as the source of electrons. We have recently reported a number of POR mutations in the patients with disordered steroidogenesis. In the first report we had described missense mutations (A287P, R457H, V492E, C569Y, and V608F) identified in four patients with defects in steroid production. Each POR variant was produced as recombinant N-27 form of the enzyme in bacteria and as full-length form in yeast. Membranes from bacteria or yeast expressing normal or variant POR were purified and their activities were characterized in cytochrome c and CYP17A1 assays. Later we have published a larger study that described a whole range of POR mutations and characterized the mutants/polymorphisms A115V, T142A, M263V, Y459H, A503V, G539R, L565P, R616X, V631I, and F646del from the sequencing of patient DNA. We also studied POR variants Y181D, P228L, R316W, G413S, and G504R that were available in public databases or published literature. Three-dimensional structure of rat POR is known and we have used this structure to deduce the structure-function correlation of POR mutations in human. The missense mutations found in patients with disordered steroidogenesis are generally in the co-factor binding and functionally important domains of POR and the apparent polymorphisms are found in regions with lesser structural importance. A variation in POR can alter the activity of all microsomal P450s, and therefore, can affect the metabolism of drugs and xenobiotics even when the P450s involved are otherwise normal. It is important to study the genetic and biochemical basis of POR variants in human population to gain information about possible differences in P450 mediated reactions among the individuals carrying a variant or polymorphic form of POR that could impact their metabolism.
Similar articles
-
Biochemical analysis of mutations in P450 oxidoreductase.Biochem Soc Trans. 2006 Dec;34(Pt 6):1186-91. doi: 10.1042/BST0341186. Biochem Soc Trans. 2006. PMID: 17073782
-
Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductase.Biochem Biophys Res Commun. 2010 Sep 24;400(3):374-8. doi: 10.1016/j.bbrc.2010.08.072. Epub 2010 Aug 21. Biochem Biophys Res Commun. 2010. PMID: 20732302
-
Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.Biochem J. 2015 May 15;468(1):25-31. doi: 10.1042/BJ20141410. Biochem J. 2015. PMID: 25728647 Free PMC article.
-
[Antley-Bixler syndrome or POR deficiency?].Cas Lek Cesk. 2008;147(5):261-5. Cas Lek Cesk. 2008. PMID: 18630181 Review. Czech.
-
P450 oxidoreductase deficiency: a new disorder of steroidogenesis.Ann N Y Acad Sci. 2005 Dec;1061:100-8. doi: 10.1196/annals.1336.012. Ann N Y Acad Sci. 2005. PMID: 16467261 Review.
Cited by
-
Suppression of cytochrome p450 reductase enhances long-term hematopoietic stem cell repopulation efficiency in mice.PLoS One. 2013 Jul 26;8(7):e69913. doi: 10.1371/journal.pone.0069913. Print 2013. PLoS One. 2013. PMID: 23922855 Free PMC article.
-
NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology.Drug Metab Dispos. 2013 Jan;41(1):12-23. doi: 10.1124/dmd.112.048991. Epub 2012 Oct 19. Drug Metab Dispos. 2013. PMID: 23086197 Free PMC article.
-
Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6.PLoS One. 2012;7(6):e38495. doi: 10.1371/journal.pone.0038495. Epub 2012 Jun 12. PLoS One. 2012. PMID: 22719896 Free PMC article.
-
Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.Eur J Clin Pharmacol. 2013 Apr;69(4):807-12. doi: 10.1007/s00228-012-1432-1. Epub 2012 Oct 25. Eur J Clin Pharmacol. 2013. PMID: 23097010 Clinical Trial.
-
Genetic variations in NADPH-CYP450 oxidoreductase in a Czech Slavic cohort.Pharmacogenomics. 2015;16(3):205-15. doi: 10.2217/pgs.14.169. Pharmacogenomics. 2015. PMID: 25712184 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources